Ole Mogensen

ORCID: 0000-0001-7655-9909 · 4 papers in corpus
diagnostic-accuracy 2024
Identifying safe diagnostic algorithms for sentinel lymph node mapping in high-risk endometrial cancer: The SENTIREC-endo study
Gynecologic Oncology ·doi:10.1016/j.ygyno.2024.01.049

INTRODUCTION: It is unclear if sentinel node (SLN) mapping can replace pelvic- (PLD) and paraaortic lymphadenectomy (PALD) for high-risk endometrial cancer (EC). A diagnostically safe surgical algorithm, taking failed mapping cases into acc…

nonrandomized-trial 2023
The SENTIREC-endo study - Risks and benefits of a national adoption of sentinel node mapping in low and intermediate risk endometrial cancer
Gynecologic Oncology ·doi:10.1016/j.ygyno.2023.02.013

OBJECTIVE: The SENTIREC-endo study aims to investigate risks and benefits of a national protocolled adoption of sentinel lymph node (SLN) mapping in women with early-stage low-grade endometrial cancer (EC) with low- (LR) and intermediate-ri…

observational 2020
Relationship between a uterine fibroid diagnosis and the risk of adverse obstetrical outcomes: a cohort study
BMJ open ·doi:10.1136/bmjopen-2019-032104

OBJECTIVE: The aim was to investigate the association between clinically significant uterine fibroids and preterm birth, caesarean section (CS), postpartum haemorrhage (PPH), placental abruption, intrauterine growth restriction (IUGR) and u…

observational 2008
Expression of the epidermal growth factor system in eutopic endometrium from women with endometriosis differs from that in endometrium from healthy women
Gynecologic and obstetric investigation ·doi:10.1159/000167798

BACKGROUND: The epidermal growth factor (EGF) system comprises four receptors, HER1-4, and several ligands, and is cyclically expressed in endometrium from healthy fertile women. Our aim is to identify differences in expression of the EGF s…